INTRODUCTION: We assessed outcomes and costs of open prostatectomy (OP) versus robotic-assisted prostatectomy (RAP) at a single tertiary care university hospital. METHODS: We retrospectively analyzed 200 consecutive OP by 1 experienced open surgeon (MG) and 200 consecutive RAP by an experienced open surgeon (SLG), after allowing for a short learning curve of 70 cases. RESULTS: The 2 groups had similar demographics, including mean age (64.7 vs. 64.2) and mean body mass index (27.2 vs. 27.2). The OP group had a higher proportion of higher risk cancers compared to the RAP group (32.5% vs. 8.5%). Mean skin-to-skin operative room time was less for the OP (114.2 vs. 234.1 minutes). Transfusion rates were similar at 1.5% with OP compared to 3.5% with RAP. The mean length of stay was 1.78 days for OP compared to 1.76 days for RAP, for the last 100 patients in each group. The OP group had more high-grade disease in the prostatectomy specimen, with Gleason ≥8 in 23.5% compared to 3.5% in the RAP group. Positive surgical margin rates were comparable at 31% for OP and 24.6% for RAP, and remained similar after stratification for pT2 and pT3 disease. The grade I and II perioperative complication rate (Clavien-Dindo classification) was lower in the OP group (8.5% vs. 20%). Postoperative stress urinary incontinence rates (4.8% for OP and 4.6% for RAP) and biochemical-free status (91.8% for OP and 96% for RAP) did not differ at 12 months post-surgery. The additional cost of RAP was calculated as $5629 per case. The main limitations of this study are its retrospective nature and lack of validated questionnaires for evaluation of postoperative functional outcomes. CONCLUSION: While hospital length of stay, transfusion rates, positive surgical margin rates and postoperative urinary incontinence were similar, OP had a shorter operative time and a lower cost compared to the very early experience of RAP. Future parallel prospective analysis will address the impact of the learning curve on these outcomes.
INTRODUCTION: We assessed outcomes and costs of open prostatectomy (OP) versus robotic-assisted prostatectomy (RAP) at a single tertiary care university hospital. METHODS: We retrospectively analyzed 200 consecutive OP by 1 experienced open surgeon (MG) and 200 consecutive RAP by an experienced open surgeon (SLG), after allowing for a short learning curve of 70 cases. RESULTS: The 2 groups had similar demographics, including mean age (64.7 vs. 64.2) and mean body mass index (27.2 vs. 27.2). The OP group had a higher proportion of higher risk cancers compared to the RAP group (32.5% vs. 8.5%). Mean skin-to-skin operative room time was less for the OP (114.2 vs. 234.1 minutes). Transfusion rates were similar at 1.5% with OP compared to 3.5% with RAP. The mean length of stay was 1.78 days for OP compared to 1.76 days for RAP, for the last 100 patients in each group. The OP group had more high-grade disease in the prostatectomy specimen, with Gleason ≥8 in 23.5% compared to 3.5% in the RAP group. Positive surgical margin rates were comparable at 31% for OP and 24.6% for RAP, and remained similar after stratification for pT2 and pT3 disease. The grade I and II perioperative complication rate (Clavien-Dindo classification) was lower in the OP group (8.5% vs. 20%). Postoperative stress urinary incontinence rates (4.8% for OP and 4.6% for RAP) and biochemical-free status (91.8% for OP and 96% for RAP) did not differ at 12 months post-surgery. The additional cost of RAP was calculated as $5629 per case. The main limitations of this study are its retrospective nature and lack of validated questionnaires for evaluation of postoperative functional outcomes. CONCLUSION: While hospital length of stay, transfusion rates, positive surgical margin rates and postoperative urinary incontinence were similar, OP had a shorter operative time and a lower cost compared to the very early experience of RAP. Future parallel prospective analysis will address the impact of the learning curve on these outcomes.
Authors: Ashutosh Tewari; Prasanna Sooriakumaran; Daniel A Bloch; Usha Seshadri-Kreaden; April E Hebert; Peter Wiklund Journal: Eur Urol Date: 2012-02-24 Impact factor: 20.096
Authors: A Heidenreich; J Bellmunt; M Bolla; S Joniau; M Mason; V Matveev; N Mottet; H P Schmid; T van der Kwast; T Wiegel; F Zattoni Journal: Actas Urol Esp Date: 2011-07-14 Impact factor: 0.994
Authors: Ian Thompson; James Brantley Thrasher; Gunnar Aus; Arthur L Burnett; Edith D Canby-Hagino; Michael S Cookson; Anthony V D'Amico; Roger R Dmochowski; David T Eton; Jeffrey D Forman; S Larry Goldenberg; Javier Hernandez; Celestia S Higano; Stephen R Kraus; Judd W Moul; Catherine M Tangen Journal: J Urol Date: 2007-06 Impact factor: 7.450
Authors: James Mohler; Robert R Bahnson; Barry Boston; J Erik Busby; Anthony D'Amico; James A Eastham; Charles A Enke; Daniel George; Eric Mark Horwitz; Robert P Huben; Philip Kantoff; Mark Kawachi; Michael Kuettel; Paul H Lange; Gary Macvicar; Elizabeth R Plimack; Julio M Pow-Sang; Mack Roach; Eric Rohren; Bruce J Roth; Dennis C Shrieve; Matthew R Smith; Sandy Srinivas; Przemyslaw Twardowski; Patrick C Walsh Journal: J Natl Compr Canc Netw Date: 2010-02 Impact factor: 11.908
Authors: Axel Heidenreich; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Malcolm Mason; Vsevolod Matveev; Nicolas Mottet; Hans-Peter Schmid; Theo van der Kwast; Thomas Wiegel; Filliberto Zattoni Journal: Eur Urol Date: 2010-10-28 Impact factor: 20.096
Authors: Quoc-Dien Trinh; Jesse Sammon; Maxine Sun; Praful Ravi; Khurshid R Ghani; Marco Bianchi; Wooju Jeong; Shahrokh F Shariat; Jens Hansen; Jan Schmitges; Claudio Jeldres; Craig G Rogers; James O Peabody; Francesco Montorsi; Mani Menon; Pierre I Karakiewicz Journal: Eur Urol Date: 2011-12-22 Impact factor: 20.096
Authors: William T Lowrance; James A Eastham; Caroline Savage; A C Maschino; Vincent P Laudone; Christopher B Dechet; Robert A Stephenson; Peter T Scardino; Jaspreet S Sandhu Journal: J Urol Date: 2012-04-11 Impact factor: 7.450
Authors: Jim C Hu; Xiangmei Gu; Stuart R Lipsitz; Michael J Barry; Anthony V D'Amico; Aaron C Weinberg; Nancy L Keating Journal: JAMA Date: 2009-10-14 Impact factor: 56.272
Authors: Florian Rudolf Schroeck; Bruce L Jacobs; Sam B Bhayani; Paul L Nguyen; David Penson; Jim Hu Journal: Eur Urol Date: 2017-03-31 Impact factor: 20.096
Authors: Jim C Hu; Padraic O'Malley; Bilal Chughtai; Abby Isaacs; Jialin Mao; Jason D Wright; Dawn Hershman; Art Sedrakyan Journal: J Urol Date: 2016-10-05 Impact factor: 7.450